Key result
Polychemotherapy in patients with lymphomas was associated with significant worsening of left ventricular diastolic function, including an increase in isovolumic relaxation time, without meeting standard criteria for systolic cardiotoxicity.
Why the study?
To evaluate the dynamics of cardiotoxicity, endothelial dysfunction, fibrosis, systemic inflammation biomarkers, and LV morpho-functional alterations in patients with newly diagnosed lymphomas during 6 courses of polychemotherapy.
Does polychemotherapy induce changes in biomarkers and left ventricular morpho-functional parameters in patients with newly diagnosed lymphomas?
Cohort (n=30)
No
Does polychemotherapy induce changes in biomarkers and left ventricular morpho-functional parameters in patients with newly diagnosed lymphomas?
Absolute Event Rate: 108% vs 103%
p-value: p=0.002
In patients with lymphomas undergoing polychemotherapy, early signs of cardiovascular toxicity manifest as endothelial dysfunction and left ventricular diastolic dysfunction before overt changes in standard cardiotoxicity biomarkers or systolic function.
May support serial biomarker monitoring for cardiotoxicity during lymphoma PCT; leaves open need for larger prospective validation.
No takes yet. Share an insight, caveat, or question.
Sokolova et al. (2024) conducted a cohort in Lymphoma (n=30). Polychemotherapy vs. Baseline was evaluated on Left ventricular isovolumic relaxation time (IVRT) in ms (p=0.002). Polychemotherapy in patients with lymphomas was associated with significant worsening of left ventricular diastolic function, including an increase in isovolumic relaxation time, without meeting standard criteria for systolic cardiotoxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: